BNGO Bionano Genomics Inc

$BNGO In 6 years Bionano has gone from 3 million a quarter to 8 million a quarter in revenue, while burning though a half of billion dollars of shareholder money while reverse splitting twice and they will be out of cash in a few more months. Anybody that invest in this company is a stupid moronic idiot

$BNGO The model is still the error. HCW slides just showed the P&L the tape refuses to price. FY27 outlook: $50–54M (+56%), 48–55 new boxes, consumables the bar, adj. EBITDA ~$0 exit Q4. FY29 plan: $101–108M, GM 58%, adj. EBITDA +$17M, flow cells 149k, install base 635. That’s utilization: maps on the installed base into live 81195 @ $1,853.22 and 81354 @ $1,263.53. MolDX draft already published for heme. TA still required. Proposed ≠ paid. The loop is the same: chips → claims → coverage → more chips. Tape cap ~$14M on a name guiding $31–33M this year and $50M+ next. Kit-company model. Wrong distribution. If they print anything like that table, the spreadsheet has to change. That’s the 15σ path — the multiple catching the flywheel already in the deck. Deck prints (base): ’27 $3–8 · ’28 $6–14 · ’29 $10–25 · ’30 $12–35 15σ (old model dies): ’27 $12–40 · ’28 $25–80 · ’29 $50–150 · ’30 $80–250 Watch flow cells and LCD final. The slide is the map. $1.20 is the error.

$BNGO I was on this in 2021. The stock ran from $.46 to $15.86. What a ride. I held a stock for five months before the run. The community on the board was the best ever. Millionaires were minted. This was my biggest win to date 200 K. She seems bullish again. Will she retrace her old steps. I’m not sure but I’ll hang out here a while. Let’s see.

$BNGO I’ve logged 75 real use cases since 2019. 108 with longer shots (nano-nozzle patent, space/radiation). FY29 ~$100M models price one or two — mostly heme. That’s the floor: heme only, other 73 at zero. Highest-probability beyond “heme kit”: • Constitutional / rare disease (81354 @ $1,263.53) • FSHD and other repeat/structure tests • Prenatal large rearrangements sequencing misses • CGT QC (release testing — different buyer) • Multi-omic reflex: OGM + sequencing • 2026 heme refinements (cryptic AML, high-risk MDS, t-MN) 81195 @ $1,853.22. 10k heme ≈ $18.5M lab-side; 10k 81354 ≈ $12.6M. Q2 chips +27%. NYSDOH LDTs. MolDX draft (final + TA still required). If a few of the 73 turn: FY29 $150–250M. Menu attaches: $250–400M into 2030. 15σ if the multiple drops: ’27 $12–40 · ’28 $25–80 · ’29 $50–150 · ’30 $80–250. They’re pricing a kit. The menu is 75–108 potential flavors of OGM.

$BNGO I had a feeling that this will runs hard like tomorrow morning just like $VEEA and $RETO today

$BNGO anyone who doesn't understand why this stock moved today has no business owning this stock, or even looking at this stock or talking about this stock. To those of you that claimed that this moved on "no news", you are either belligerent liars, or morons.

$BNGO Am I reading this right? Avg volume 141k, today's volume 33 million? Maybe I'm reading the wrong chart, this seems unrealistic.

$BNGO don't trade on hope...you will forever be the loser. 50% return could have been had... instead you post juvenile gif's with no substance. you're a grown man ...maybe post grown man ideas.

$BNGO peer review and OGM validation was a given. the problem was there is little money in academia and sales were ham strung by the use in only that narrow sector The double wrapped beef burro is.. CPT code (81195) for OGM in hematologic malignancies with an active 2026 reimbursement rate of $1,853.22 per test. Final approval from MolDX would effectively unlock this reimbursement pipeline for Medicare patients, which Bionano estimates could eventually influence coverage for up to 60% of the U.S. population as private insurers typically mirror Medicare guidelines. that is $1,853.22 per test! 18 benjamins an a grant is f you money. of course there will be the funny money medicare adjustments... imo...bank

$BNGO so funny how bears today have come to believe that every stock offering is a death sentence. Believe me..every trilion dollar company today once did multiple stock offerings. I'm not saying that bngo will get there, but this idea that stock offerings or reverse splits are the end of the company is insane.

$BNGO for any bulls creaming their pants right now… ZOOM OUT ON THE CHART… then take a deep breath and remeber EVERY RALLY means an offering is coming up at BioScamo

$BNGO The worst investment of my life, not much but still criminal. This company should vanish from the earth .

$BNGO has anyone tried to calculate how much revenue bngo could generate from the MoIDX authorization? Even 30 million annually would be a huge deal.

$BNGO over three times outstanding shares crossed the board so far. volatile trading at its best...both ways. independent peer review... affirmation that OGM platform is legit & superior to FISH. Bionano will commercialize genome analysis. leaving academic use in the rear view. forward guidance @ 50% + growth by 2027. complete Medicare approval is at the 5 yard line. let that sink in. nice quinella move this morning but lets see what happens with the algo day trading throughout the rest of the day and in to tomorrow.

$BNGO News from Finviz: Clinical OGM studies and growth roadmap drive BNGO 33% surge Three independent peer-reviewed studies (MD Anderson, Univ of Oulu, Josep Carreras) released Sept 14 show OGM detects high-risk variants in MDS, AML, t-MN missed by karyotyping/FISH. Studies link OGM findings like chromoanagenesis and TP53 disruption to worse survival and improved risk reclassification/prognosis. Sept 14 Wainwright conference presentation and 8-K detail 71% OpEx cuts, 53% gross margins, FY26 revenue $31-33M, scaling to $101-108M by 2029 with path to positive EBITDA. Builds on recent wins including proposed MolDX Medicare LCD (Sept 10), NY DOH OGM approval (Sept 8), and established CPT codes for reimbursement. Low-float stock (~11.8M shares) experiences explosive volume and momentum trading on Sept 15 with no new overhang. Follow-through buying after +9% close on Sept 14; clinical validation plus financial transformation catalyze retail and investor interest.

$BNGO 19% from our first alert. 1.4x rel vol, float rotating, RSI sitting at 93. Strong bull on the macro.

$BNGO The modeling error is the whole trade. Fair value just ticked $5 → $6. They ran BNGO as a normal microcap kit company: no paid code, no utilization loop, cheap-for-a-reason. That model cannot hold 81195 at $1,853.22, Q2 chips +27% with demand still ahead of the factory, NYSDOH OGM LDTs, and a MolDX draft that says one genome-wide SV assay can replace banding + FISH + CMA. So the tape sits ~$1.22 while the assay is already in clinic. Wrong distribution. Wrong multiple. SWS moving $5 to $6 is the spreadsheet flinching — cheaper discount rate on the same name. McCarthy left Buy / $4 on. First tick, not the destination. They priced a science project. The maps were already running. $6 is the model starting to admit it.

$BNGO well, so with all the reverse...45k later and here I am at $1850 (one thousand eight hundred and fifty) I for one wont live long enough to see the neon lights 🤯

$BNGO I am very well acquainted and fond of BNGO. From the very first time that I saw Beach, Blanket Bingo with Frankie Avalon, Annette Funicello and Pearl Bailey, I knew I had a winning stock that would bring me a fortune.

⏱️ One-Hour Volume Alert Update $BNGO near $1.89 • 28.76x RVOL Day Range: $1.32 - $2.00 $VEEA near $5.97 • 21.86x RVOL Day Range: $4.31 - $6.68 $VRA near $3.51 • 19.11x RVOL Day Range: $3.25 - $3.62 Unusual volume does not guarantee direction—it highlights attention. Not financial advice.